Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Public ClinicalTrials.gov record NCT05588609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase II, open-label, 2-arm, multicenter, international study designed to evaluate the efficacy of zenocutuzumab alone or in combination in patients with the following diagnoses: Group A: NRG1+ NSCLC Group B: mCRPC
Study identification
- NCT ID
- NCT05588609
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 13 participants
Conditions and interventions
Interventions
- Afatinib Oral Tablet Drug
- Enzalutamide Pill Drug
- Abiraterone acetate tablets Drug
- MCLA-128 Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 16, 2022
- Primary completion
- Jul 2, 2025
- Completion
- Jul 2, 2025
- Last update posted
- Apr 26, 2026
2022 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Oncology Institute of Hope & Innovation | Whittier | California | 90603 | — |
| Florida Cancer Specialists | Lake Mary | Florida | 32746 | — |
| The Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| TriHealth Cancer Institute | Cincinnati | Ohio | 45220 | — |
| University Hospitals - Seidman Cancer Center | Cleveland | Ohio | 44106 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated NSCLC Harboring NRG1 Fusion trials
Other public records listing NSCLC Harboring NRG1 Fusion. Sorted by last update posted; newest first. Not a recommendation.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05588609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 26, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05588609 live on ClinicalTrials.gov.